Addenbrooke’s hospital offers first self-service digital eye test
July 17, 2025Research and Development Addenbrooke's Hospital, Cambridge, Opthalmology, UK, eye test, ophthalmology
Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing system – DigiVis DVA system …
Biogen and Stoke report positive results for Dravet syndrome drug
July 17, 2025Research and Development Biogen, Dravet Syndrome, Neurology, Stoke Therapeutics, epilepsy, rare diseases
Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which is being developed for Dravet …
FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
July 16, 2025Medical Communications COVID-19, Spikevax, US Food and Drug Administration, Vaccine, Virology
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, Spikevax, in children aged six …
Jazz Pharmaceuticals appoints Renée Galá as CEO to lead next phase of growth
July 16, 2025Research and Development CEO, Corporate, Neurology, Oncology, jazz pharmaceuticals, neurology, neuroscience
Jazz Pharmaceuticals has named Renée Galá as its next chief executive officer (CEO), effective 11 August 2025. Galá, currently president …
Osivax publishes positive results from trial of influenza vaccine candidate
July 15, 2025Research and Development Osivax, Vaccine, Virology, clinical trial, influenza, respiratory diseases
French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, its broad-spectrum influenza vaccine lead …
Pharvaris to report phase 3 data and submit New Drug Application
July 15, 2025Medical Communications, Research and Development Pharvaris, Rare Diseases, US Food and Drug Administration, clinical trial, genetic condition, new drug application
Pharvaris has announced that its data from its phase 3 study of deucrictibant immediate-release capsules (IR) for the treatment of …
Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders
July 14, 2025Mergers and Acquisitions, Research and Development Neurology, Secarna Pharmaceuticals, Vect-Horus, central nervous system, neurodegenerative conditions
Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics capable of crossing the blood-brain …
VIVES Partners contributes to €84m funding for radiopharma company, Nuclidium
July 14, 2025Medical Communications, Research and Development Nuclidium, Oncology, VIVES Funds, VIVES Partners, radiopharmaceuticals, radiotheranostics
VIVES Partners, the managing company of VIVES Funds, has announced that it will contribute to an €84m Series B financing …
Cube Biotech appoints Joachim Kreuzburg to its board of directors
July 11, 2025Research and Development Corporate, Cube Biotech, IBA Life Sciences, Sartorius, archimed, board of directors, membrane protein production
German-based Cube Biotech announced the appointment of Joachim Kreuzburg to its board of directors. This will support the development of …
NICE recommends NHS use of mirikizumab for Crohn’s disease
July 11, 2025Medical Communications, Research and Development Crohn’s disease, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency, NHS, National Institute for Health and Care Excellence (NICE), bowel disease, clinical trial
Eli Lilly (Lilly) has announced that the National Institute for Health and Care Excellence (NICE) has recommended mirikizumab (omvoh) for …
BioMed X and Servier launch Europe’s first XSeed Labs to advance AI-powered antibody design
July 11, 2025Research and Development BioLabs, BioMed X, Cancer, Oncology, Servier, XSeed Labs, antibody therapy, oncology
BioMed X and Servier have announced the launch of Europe’s first XSeed Labs research project, located at the Spartners incubator …
Norstella appoints Kris Joshi as CEO to drive next phase of growth
July 10, 2025Business Services, Consultancy CEO, Corporate, HealthTech, Norstella
Pharma intelligence solutions provider, Norstella, has appointed health-tech leader, Kris Joshi, as its new chief executive officer (CEO) with former …
Amarna Therapeutics and NorthX Biologics collaborate to advance gene therapy for type 1 diabetes
July 10, 2025Mergers and Acquisitions, Research and Development Amarna Therapeutics, Diabetes, Immunology, NorthX Biologics, Type 1 diabetes, gene therapy, immune-mediated diseases
Amarna Therapeutics and NorthX Biologics have finalised an agreement to accelerate the development of Nimvec AM510, a gene therapy targeting …
Eppendorf Award for Young European Investigators 2025 awarded to neuroscientist Varun Venkataramani
July 10, 2025Medical Communications, Medical/ Scientific Writing, Research and Development Neurology, Oncology
Varun Venkataramani, of Heidelberg University Hospital, Germany, has been awarded the 2025 Eppendorf Award for Young European Investigators for his …
First malaria medicine for infants under 4.5kg receives approval
July 9, 2025Medical Communications, Research and Development Coartem Baby, Infections and infestations, Medicines for Malaria Venture, Novartis, Paediatrics, Swissmedic, malaria
Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine for newborns and young infants. …
First adult in the UK given new treatment for type 1 diabetes
July 9, 2025The first adult in the UK to trial Tepilzumab for type 1 diabetes has started treatment at the Royal Devon …
Richard Philipson appointed as chief medical officer of Hansa Biopharma
July 9, 2025Research and Development Hansa Biopharma, Immunology, chief medical officer, immunology
Hansa Biopharma has announced that Richard Philipson has been appointed chief medical officer, effective 14 July. Philipson will join the …
Ciloa secures €6.5m from French government to advance obesity and T2 diabetes therapy
July 9, 2025Research and Development Ciloa, Diabetes, France 2030, Obesity, adiponectin, funding, obesity, type 2 diabetes
French biotech company, Ciloa, has received €6.5m in funding through France 2030 to advance its lead candidate, APN-sEV, targeting obesity …
Duke Street Bio receives FDA fast track designation for brain metastases treatment
July 8, 2025Medical Communications, Research and Development Duke Street Bio, Oncology, US Food and Drug Administration, brain metastases, breast cancer, fast track designation
Duke Street Bio, a biotech company based in London, UK, has announced that the US Food and Drug Administration (FDA) …
SMC recommends Eladynos for postmenopausal osteoporosis in Scotland
July 8, 2025Medical Communications, Research and Development Musculo-skeletal disorder, NHS, Scottish Medicine Consortium, Theramex, clinical trials, osteoporosis, postmenopause
Theramex, a women’s health pharma company, has announced that the Scottish Medicines Consortium has recommended Eladynos (abaloparatide) for NHS use …
Latest content
FibroFind appoints Lee Borthwick as CEO
